YU 238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-De fi cient Tumors

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

  2014cited by this paper
• Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors

  2014cited by this paper
• Five-year relative survival rate of ovarian cancer in the USA, Europe and Japan.

  2014cited by this paper
• Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.

  2014cited by this paper
• The novel HDAC inhibitor NDACI054 sensitizes human cancer cells to radiotherapy.

  2013cited by this paper
• The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

  2013cited by this paper
• RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination

  2013influential reference
• Realizing the opportunities of genomics in health care.

  2013cited by this paper
• A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

  2013cited by this paper
• Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells

  2012cited by this paper
• A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

  2012cited by this paper
• Base excision repair: contribution to tumorigenesis and target in anticancer treatment paradigms.

  2012cited by this paper
• I-SceI-based assays to examine distinct repair outcomes of mammalian chromosomal double strand breaks.

  2012cited by this paper
• Base excision repair and cancer.

  2012cited by this paper
• Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR.

  2011cited by this paper
• Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

  2010cited by this paper
• Therapeutic Targeting of the DNA Mismatch Repair Pathway

  2010cited by this paper
• The tumor microenvironment and DNA repair.

  2010cited by this paper
• Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation.

  2010cited by this paper
• Ovarian cancer development and metastasis.

  2010cited by this paper
• A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex.

  2008cited by this paper
• Nucleotide excision repair and cancer

  2006cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2.

  2005influential reference
• Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.

  2005cited by this paper
• Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

  2004cited by this paper
• Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries.

  2004cited by this paper
• Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization.

  2003cited by this paper
• Wortmannin sensitizes mammalian cells to radiation by inhibiting the DNA-dependent protein kinase-mediated rejoining of double-strand breaks.

  1999cited by this paper
• XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.

  1999cited by this paper
• Genetic analysis of BRCA1 function in a defined tumor cell line.

  1999cited by this paper
• Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

  1997cited by this paper
• Loss of DNA mismatch repair in acquired resistance to cisplatin.

  1996cited by this paper
• Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma

  year unknowncited by this paper

• No citing papers are available for this paper.